Literature DB >> 22791600

Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.

T Weber1, D Ohlhauser, A Hillenbrand, D Henne-Bruns, S N Reske, M Luster.   

Abstract

Fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomography (CT) is able to localize persistent or recurrent disease in differentiated thyroid carcinoma (DTC). The aim of the study was to correlate PET/CT results with precise intraoperative localization of persistent or recurrent papillary and follicular thyroid carcinoma. Patients with differentiated thyroid carcinoma who received FDG-PET scans were prospectively documented. The PET/CT results were correlated with other localization studies (neck ultrasound, ¹³¹I whole-body scan) and accurately compared to intraoperative findings and histopathological examinations. FDG-PET/CT scans were performed in 18 patients, between 16 and 84 years of age, from December 2008 to June 2011. Fourteen patients had papillary thyroid carcinomas and 4 had follicular thyroid carcinomas. All patients had a previous thyroidectomy and radioiodine ablation. Before cervical re-exploration, FDG-PET/CT-positive findings were reported in 14 individuals, whereas 4 PET scans provided no evidence of disease. Intraoperatively, 13 of 14 FDG-PET/CT-positive localizations of recurrent or persistent thyroid carcinomas were verified and confirmed by histopathology (sensitivity 93%). In another patient lymph node metastases of lung cancer were detected intraoperatively. However, FDG-PET/CT underestimated the number of lesions in 5 of 6 patients undergoing systematic lymphadenectomy. No lymph node or soft tissue metastases were found intraoperatively in 3 of the 4 patients with negative FDG-PET scans. A solitary cystic lymph node metastasis was found in the fourth patient but was not detected by FDG-PET/CT (specificity 75%). FDG-PET/CT has high sensitivity and specificity for the detection of persistent or recurrent differentiated thyroid carcinoma. FDG-PET/CT helps to select patients who might benefit from surgery because it provides precise anatomical details. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22791600     DOI: 10.1055/s-0032-1316351

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  6 in total

1.  Expression status of cytoskeleton regulatory protein Mena as a prognostic marker for human thyroid carcinoma.

Authors:  Ruilei Liu; Ruiming Liu; Jie Li; Yu Liu; Hua Jiang; Shenming Wang
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

2.  Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer.

Authors:  Jaime L Wiebel; Nazanene H Esfandiari; Maria Papaleontiou; Francis P Worden; Megan R Haymart
Journal:  Thyroid       Date:  2015-08-03       Impact factor: 6.568

3.  Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis.

Authors:  Friederike Schütz; Christine Lautenschläger; Kerstin Lorenz; Johannes Haerting
Journal:  Eur Thyroid J       Date:  2017-10-24

4.  Post-PET ultrasound improves specificity of 18F-FDG-PET for recurrent differentiated thyroid cancer while maintaining sensitivity.

Authors:  Martin Biermann; Jostein Kråkenes; Katrin Brauckhoff; Hans Kristian Haugland; Achim Heinecke; Lars A Akslen; Jan Erik Varhaug; Michael Brauckhoff
Journal:  Acta Radiol       Date:  2015-03-13       Impact factor: 1.990

5.  Incremental Value of a Dedicated Head and Neck Acquisition during 18F-FDG PET/CT in Patients with Differentiated Thyroid Cancer.

Authors:  Renaud Ciappuccini; Nicolas Aide; David Blanchard; Jean-Pierre Rame; Dominique de Raucourt; Jean-Jacques Michels; Emmanuel Babin; Stéphane Bardet
Journal:  PLoS One       Date:  2016-09-06       Impact factor: 3.240

6.  Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer.

Authors:  Johann-Martin Hempel; Roman Kloeckner; Sandra Krick; Daniel Pinto Dos Santos; Simin Schadmand-Fischer; Patrick Boeßert; Sotirios Bisdas; Matthias M Weber; Christian Fottner; Thomas J Musholt; Mathias Schreckenberger; Matthias Miederer
Journal:  Cancer Imaging       Date:  2016-11-03       Impact factor: 3.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.